EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Real-world outcomes of mepolizumab treatment in severe eosinophilic asthma patients - retrospective cohort study in Slovakia

Milos Jesenak, Vaclav Vanecek, Martina Ondrusova, Veronika Urdova, Katarina Dostalova, Ludek Hochmuth

Biomedical Papers · 2023

DOI: 10.5507/bp.2023.029 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Biomedical Papers, 2023. Verfasst von Milos Jesenak und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Immunology and Allergology, University Teaching Hospital in Martin, Martin, Slovakia. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Asthma, Eosinophilia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Mepolizumab, a fully-humanized recombinant IgG1 kappa monoclonal antibody directed against IL-5, has shown improved asthma control and lung function in randomised controlled trials. The aim of this study was to evaluate real-world clinical experience in patients with severe eosinophilic asthma treated with mepolizumab in Slovakia. METHODS: A retrospective, non-interventional study based on medical records of all adult asthma patients initiating mepolizumab between November 1, 2017 and January 31, 2019, completing 12 months of treatment. At baseline, general and clinical profile data were recorded 12 months prior to treatment. Primary and secondary endpoints described the results of mepolizumab use at 2, 6, and 12 months after the initiation and compared to baseline. Statistical testing of individual change (in each patient) in selected parameters was performed. RESULTS: The cohort included 17 patients with particularly severe asthma at baseline, with frequent severe exacerbations (SE, median 5 [IQR 4-6]/patient/year), high blood eosinophil counts (median 0.6x109/L), frequent oral corticosteroid (OCS) dependence (82.35%), median dose 15 (IQR 7.5-20) mg/day, impaired lung function, and a spectrum of comorbidities. In a one-year follow-up, the data showed reductions in median SE (0 [IQR 0-1] patient/year, eosinophilia (median 0.175x109/L) and OCS maintenance dose (median 6.25 [IQR 2.5-20] mg/day), all statistically significant after 12 months on mepolizumab. Improved and stabilised lung functions throughout the cohort and a reduced incidence of nasal polyposis were observed. CONCLUSIONS: The results provide clinical evidence of mepolizumab efficacy in a real sample of patients with severe asthma when administered in routine care settings in Slovakia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Asthmatic AgentsAsthmaEosinophiliaAdultHumansRetrospective StudiesSlovakiaAdrenal Cortex HormonesAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Slovakiaexacerbationsmepolizumabreal world evidencesevere eosinophilic asthma

Substanzen

Anti-Asthmatic AgentsAdrenal Cortex HormonesmepolizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Clinical Immunology and Allergology, University Teaching Hospital in Martin, Martin, Slovakia.
  • Department of Pulmonology and Phthisiology, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Teaching Hospital in Martin, Martin, Slovakia.
  • Department of Paediatrics, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, University Teaching Hospital in Martin, Martin, Slovakia.
  • GlaxoSmithKline, Medical Department, Prague, Czech Republic.
  • Pharm-In, Ltd, Bratislava, Slovakia.
  • Faculty of Public Health, Slovak Medical University, Bratislava, Slovakia.

Zitieren

APA

Jesenak, M., Vanecek, V., Ondrusova, M., Urdova, V., Dostalova, K., & Hochmuth, L. (2023). Real-world outcomes of mepolizumab treatment in severe eosinophilic asthma patients - retrospective cohort study in Slovakia. Biomedical Papers. https://doi.org/10.5507/bp.2023.029

Vancouver

Jesenak M, Vanecek V, Ondrusova M, Urdova V, Dostalova K, Hochmuth L. Real-world outcomes of mepolizumab treatment in severe eosinophilic asthma patients - retrospective cohort study in Slovakia. Biomedical Papers. 2023. doi:10.5507/bp.2023.029

BibTeX
@article{Jesenak2023,
  author = {Jesenak, Milos and Vanecek, Vaclav and Ondrusova, Martina and Urdova, Veronika and Dostalova, Katarina and Hochmuth, Ludek},
  title = {Real-world outcomes of mepolizumab treatment in severe eosinophilic asthma patients - retrospective cohort study in Slovakia},
  journal = {Biomedical Papers},
  year = {2023},
  doi = {10.5507/bp.2023.029}
}
Kostenlos starten →